Atlas Trials

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

Clinical trial NCT07455071 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07455071
Sponsor
Peking University Third Hospital
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
HRD-negative Epithelial Ovarian Cancer
Start date
2026-03-01
Primary completion
2027-09-30
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.